Loading...

Epizyme

DB:EPE
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
EPE
DB
$1B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The last earnings update was 55 days ago. More info.


Add to Portfolio Compare Print
  • Epizyme has significant price volatility in the past 3 months.
EPE Share Price and Events
7 Day Returns
-1.9%
DB:EPE
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-11.6%
DB:EPE
-10.2%
DE Biotechs
-6%
DE Market
EPE Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Epizyme (EPE) -1.9% 5.2% 34.7% -11.6% 3.5% -24.1%
DE Biotechs -2.4% 3.8% -8.6% -10.2% 51.2% 10.1%
DE Market 1.8% 6% 7.8% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • EPE underperformed the Biotechs industry which returned -10.2% over the past year.
  • EPE underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
EPE
Industry
5yr Volatility vs Market
Related Companies

EPE Value

 Is Epizyme undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Epizyme. This is due to cash flow or dividend data being unavailable. The share price is €11.18.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Epizyme's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Epizyme's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:EPE PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.72
NasdaqGS:EPZM Share Price ** NasdaqGS (2019-04-18) in USD $12.68
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Epizyme.

DB:EPE PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:EPZM Share Price ÷ EPS (both in USD)

= 12.68 ÷ -1.72

-7.37x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Epizyme is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Epizyme is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Epizyme's expected growth come at a high price?
Raw Data
DB:EPE PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.37x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
41%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Epizyme, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Epizyme's assets?
Raw Data
DB:EPE PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $2.94
NasdaqGS:EPZM Share Price * NasdaqGS (2019-04-18) in USD $12.68
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:EPE PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:EPZM Share Price ÷ Book Value per Share (both in USD)

= 12.68 ÷ 2.94

4.31x

* Primary Listing of Epizyme.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Epizyme is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Epizyme's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Epizyme has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

EPE Future Performance

 How is Epizyme expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
41%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Epizyme expected to grow at an attractive rate?
  • Epizyme's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Epizyme's earnings growth is expected to exceed the Germany market average.
  • Epizyme's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:EPE Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:EPE Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 41%
DB:EPE Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts 49.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:EPE Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:EPE Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 407 101 4
2022-12-31 261 30 6
2021-12-31 128 -96 6
2020-12-31 41 -146 8
2019-12-31 7 -167 7
DB:EPE Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 22 -122 -124
2018-09-30 12 -129 -137
2018-06-30 12 -133 -137
2018-03-31 10 -118 -136
2017-12-31 10 -120 -134
2017-09-30 10 -111 -133
2017-06-30 17 -97 -120
2017-03-31 8 -104 -120
2016-12-31 8 -96 -110
2016-09-30 8 -97 -97
2016-06-30 2 -79 -96
2016-03-31 2 -76 -94

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Epizyme's earnings are expected to grow significantly at over 20% yearly.
  • Epizyme's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:EPE Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from Epizyme Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:EPE Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.02 1.31 0.56 3.00
2022-12-31 0.32 1.49 -0.52 5.00
2021-12-31 -1.03 -0.67 -1.33 4.00
2020-12-31 -1.63 -0.82 -1.94 6.00
2019-12-31 -2.09 -1.61 -2.54 8.00
DB:EPE Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.72
2018-09-30 -1.97
2018-06-30 -2.04
2018-03-31 -2.11
2017-12-31 -2.18
2017-09-30 -2.27
2017-06-30 -2.06
2017-03-31 -2.07
2016-12-31 -1.93
2016-09-30 -1.84
2016-06-30 -1.96
2016-03-31 -2.09

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Epizyme will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Epizyme's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Epizyme has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

EPE Past Performance

  How has Epizyme performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Epizyme's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Epizyme does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Epizyme's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Epizyme's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Epizyme's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Epizyme Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:EPE Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 21.70 -123.63 43.97
2018-09-30 12.00 -136.85 40.23
2018-06-30 12.00 -136.96 38.02
2018-03-31 10.00 -135.85 38.27
2017-12-31 10.00 -134.31 37.18
2017-09-30 10.48 -133.16 36.33
2017-06-30 17.06 -119.90 34.54
2017-03-31 7.54 -119.86 30.80
2016-12-31 8.01 -110.21 28.37
2016-09-30 8.08 -97.42 26.81
2016-06-30 1.86 -96.15 25.96
2016-03-31 2.12 -93.93 24.51
2015-12-31 2.56 -132.38 23.90
2015-09-30 12.35 -125.19 22.82
2015-06-30 20.17 -121.82 21.81
2015-03-31 28.93 -109.45 21.15
2014-12-31 41.41 -55.01 20.87
2014-09-30 67.38 -24.04 20.31
2014-06-30 67.65 -14.04 18.23
2014-03-31 72.99 -2.98 16.00
2013-12-31 68.48 -3.75 14.04
2013-09-30 41.06 -21.14 12.00
2013-06-30 47.95 -10.38 10.04
2013-03-31 48.45 -7.72 8.60
2012-12-31 45.22 -1.19 7.51

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Epizyme has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Epizyme has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Epizyme improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Epizyme's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Epizyme has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

EPE Health

 How is Epizyme's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Epizyme's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Epizyme is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Epizyme's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Epizyme's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3949.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Epizyme Company Filings, last reported 3 months ago.

DB:EPE Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 233.01 0.07 240.30
2018-09-30 171.83 0.07 180.78
2018-06-30 205.58 0.07 215.62
2018-03-31 231.13 0.00 247.92
2017-12-31 235.37 0.11 276.44
2017-09-30 268.19 0.27 307.23
2017-06-30 150.04 0.43 193.00
2017-03-31 174.52 0.58 211.16
2016-12-31 201.70 0.73 242.19
2016-09-30 233.80 0.88 263.34
2016-06-30 255.16 1.02 288.62
2016-03-31 279.01 1.16 312.66
2015-12-31 169.53 1.29 208.32
2015-09-30 189.55 1.42 229.94
2015-06-30 208.91 1.55 236.70
2015-03-31 218.37 1.68 244.50
2014-12-31 160.28 0.00 190.10
2014-09-30 172.75 0.00 211.67
2014-06-30 189.60 0.00 229.87
2014-03-31 200.64 0.00 237.06
2013-12-31 104.31 0.00 123.56
2013-09-30 87.28 0.00 139.58
2013-06-30 96.13 0.00 148.69
2013-03-31 18.04 0.00 85.05
2012-12-31 25.03 0.00 97.98
  • Epizyme's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (0% vs 0% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Epizyme has sufficient cash runway for 2 years based on current free cash flow.
  • Epizyme has sufficient cash runway for 1.9 years if free cash flow continues to grow at historical rates of 13.4% each year.
X
Financial health checks
We assess Epizyme's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Epizyme has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

EPE Dividends

 What is Epizyme's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Epizyme dividends. Estimated to be 0% next year.
If you bought €2,000 of Epizyme shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Epizyme's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Epizyme's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:EPE Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:EPE Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Epizyme has not reported any payouts.
  • Unable to verify if Epizyme's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Epizyme's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Epizyme has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Epizyme's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Epizyme's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Epizyme afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Epizyme has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

EPE Management

 What is the CEO of Epizyme's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rob Bazemore
COMPENSATION $3,589,569
AGE 50
TENURE AS CEO 3.6 years
CEO Bio

Mr. Robert B. Bazemore, Jr., also known as Bob, has been the Chief Executive Officer and President at Epizyme, Inc. since September 10, 2015 and serves as its Secretary. Mr. Bazemore served as the Chief Operating Officer of Synageva BioPharma Corp. since September 2014. Mr. Bazemore served as President of Janssen Biotech, Inc. He was responsible for the growth and diversification of the U.S. Immunology and Oncology businesses, including major brands such as Remicade(R)(infliximab) and Procrit(R)(epoetin alfa), and the launches of Simponi(R)(golimumab), Stelara(R) (ustekinumab), Zytiga(R)(abiraterone) and Imbruvica(R)(ibrutinib), among others. He served as Vice President of Capital Planning - Carolinas & Florida at Progress Energy Inc. Mr. Bazemore served as Vice President of Capital Planning at Florida Power Corp. He has over 22 years of biopharmaceutical experience, with 12 years at Johnson & Johnson in various roles including Vice President, Ethicon New Growth Platforms. He also served as Vice President, Marketing and Sales of Centocor Ortho Biotech, Inc., and Worldwide Vice President, Global Strategic Marketing. He served as Vice President of Capital Planning & Control of Progress Energy Inc. since June 1, 2005. He served as Chief Accounting Officer of Progress Energy Inc. since June 2000 and also served as its Vice President of Capital Planning & Control and Vice President of Regulated Fuels. He served as Chief Accounting Officer of Florida Progress Corporation since November 30, 2000. He served as Chief Accounting Officer and Controller of Duke Energy Progress, Inc. from May 2000 to May 2006 and as Chief Accounting Officer of North Carolina Natural Gas Corporation since December 2000. He began his career at Johnson & Johnson in 2002 and held numerous senior commercial positions having led the worldwide immunology portfolio strategy and the launches of multiple new products and indications. He worked at Merck & Co., Inc. for eleven years in roles of increasing responsibility in Medical Affairs, Sales and Marketing, including Worldwide Marketing, Respiratory Franchise Business Group and was a Member of the marketing team that launched Singulair(R) (montelukast) in the U.S. Mr. Bazemore served as Vice President and Controller of Florida Progress Corporation since November 30, 2000. Mr. Bazemore served as Vice President of Accounting with Progress Energy Inc., since 2000 and Controller since June 2000. He served as Controller of Duke Energy Florida, Inc. (alternate name Florida Power Corporation) since November 30, 2000 and its Chief Accounting Officer. He served as Vice President of Progress Energy Service Company LLC and Controller of Progress Energy Service Company LLC, the Subsidiaries of Progress Energy Inc. since 2000. Prior to joining Progress Energy, Mr. Bazemore worked in Managerial and accounting positions with companies in Roanoke, VA and Jacksonville, FL. He served as Controller of North Carolina Natural Gas Corporation from November 2000 to December 2001 and a Director of Carolina Power & Light Company, Operations & Environmental Support Department from December 1998 to May 2000 and Manager of Carolina Power & Light Company, Financial & Regulatory Accounting from September 1995 to December 1998. He has been a Director at Neon Therapeutics, Inc. since November 7, 2018. He has been a Director of Epizyme, Inc. since September 2015. He served as Chairman of Pennsylvania Bio. He serves as a Director of Pennsylvania Bio. He serves as Out side Director of AgCarolina Farm Credit, ACA (alternate name AgCarolina Financial, ACA). He obtained a Bachelor of Science in Biochemistry from the University of Georgia.

CEO Compensation
  • Rob's compensation has increased whilst company is loss making.
  • Rob's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Epizyme management team in years:

0.5
Average Tenure
50
Average Age
  • The average tenure for the Epizyme management team is less than 2 years, this suggests a new team.
Management Team

Rob Bazemore

TITLE
President
COMPENSATION
$4M
AGE
50
TENURE
3.6 yrs

Matt Ros

TITLE
Chief Strategy & Business Officer and Principal Financial Officer
COMPENSATION
$1M
AGE
51
TENURE
0.3 yrs

H. Horvitz

TITLE
Co-Founder & Chairman of the Scientific Advisory Board

Yi Zhang

TITLE
Scientific Co-Founder & Member of The Scientific Advisory Board

Joseph Beaulieu

TITLE
Controller
AGE
37
TENURE
0.3 yrs

Jason Fredette

TITLE
Vice President of Investor Relations

John Weidenbruch

TITLE
General Counsel
AGE
57

Andrea Edwards

TITLE
Head of Human Resources & Organizational Development

Pam Strode

TITLE
Senior Vice President of Regulatory Affairs & Quality Assurance

Shefali Agarwal

TITLE
Chief Medical Officer
AGE
44
TENURE
0.8 yrs
Board of Directors Tenure

Average tenure and age of the Epizyme board of directors in years:

6.6
Average Tenure
60
Average Age
  • The tenure for the Epizyme board of directors is about average.
Board of Directors

Dave Mott

TITLE
Chairman
COMPENSATION
$173K
AGE
53
TENURE
3 yrs

Rob Bazemore

TITLE
President
COMPENSATION
$4M
AGE
50
TENURE
3.6 yrs

H. Horvitz

TITLE
Co-Founder & Chairman of the Scientific Advisory Board

Yi Zhang

TITLE
Scientific Co-Founder & Member of The Scientific Advisory Board

Carl Goldfischer

TITLE
Independent Director
COMPENSATION
$170K
AGE
59
TENURE
9.6 yrs

George Daley

TITLE
Member of the Scientific Advisory Board

Bruce Chabner

TITLE
Member of the Scientific Advisory Board
AGE
77

Chris Walsh

TITLE
Member of the Scientific Advisory Board
AGE
74

Beth Seidenberg

TITLE
Independent Director
COMPENSATION
$145K
AGE
61
TENURE
11.2 yrs

Joel Huff

TITLE
Member of the Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
05. Oct 18 Buy New Enterprise Associates Company 05. Oct 18 05. Oct 18 416,667 €7.82 €3,258,003
X
Management checks
We assess Epizyme's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Epizyme has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

EPE News

Simply Wall St News

EPE Company Info

Description

Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors. It also develops tazemetostat in combination with R-CHOP that is in the Phase Ib/II clinical trials in elderly patients with DLBCL; and tazemetostat in combination with PD-L1 inhibitor, which is in the Phase Ib/II clinical trials for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer. In addition, the company is developing EZM8266, a G9a inhibitor that is in the Phase 1 study for the treatment of sickle cell disease; pinometostat, which is in the preclinical studies stage for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor that is in Phase II clinical trial for patients with solid tumors and NHL; and PRMT1 inhibitor, which is in the Phase 1 clinical trial. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Study Association; and Eisai Co. Ltd. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Details
Name: Epizyme, Inc.
EPE
Exchange: DB
Founded: 2007
$1,004,943,758
89,230,173
Website: http://www.epizyme.com
Address: Epizyme, Inc.
400 Technology Square,
4th Floor,
Cambridge,
Massachusetts, 02139,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS EPZM Common Stock Nasdaq Global Select US USD 31. May 2013
DB EPE Common Stock Deutsche Boerse AG DE EUR 31. May 2013
Number of employees
Current staff
Staff numbers
124
Epizyme employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 21:54
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/12
Last earnings filing: 2019/02/26
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.